Evidence-based prevention (EBP): A review of cytochrome P450 expression in the bronchial epithelium and new approach to lung cancer prevention

  • Tsunehiro Oyama
  • Toyohi Isse
  • Tomoe Murakami
  • Rie Suzuki-Narai
  • Masanori Ogawa
  • Tetsunosuke Yamaguchi
  • Tsuyoshi Kinaga
  • Yasunori Yashima
  • Shinichi Ozaki
  • Yong-Dae Kim
  • Heon Kim
  • Toshihiro Kawamoto
Review Article


The number of fatalities in Japan attributable to lung cancer exceeded 50000 in 2001. It is socially desirable that various markers, which can be utilized for the prevention of lung cancer, be established. We believe that smoking or exposure to carcinogens in air induces mutations in bronchial and alveolar epithelia, leading to the development of lung cancer. It would be useful to have markers of individual differences in susceptibility to chemical carcinogen-induced lung cancer 1) to identify genetic polymorphisms of enzymes metabolizing chemical carcinogens and 2) to investigate the expression of enzymes metabolizing chemical carcinogens. In this paper, we review CYP expression in the bronchial epithelium. CYP1, CYP2 and CYP3 are expressed in the bronchial epithelium. We also show the relationship between the genetic polymorphisms of cytochrome P450 (CYP) and a person’s susceptibility to chemical carcinogen-induced lung cancer. We demonstrate the relationship between cigarette consumption and the CYP expression profile in the bronchial epithelium. To maintain and promote public health, we must apply evidence, such as CYP polymorphisms and CYP profiles to disease prevention and also to aggressively advance evidence-based prevention (EBP) of lung cancer.

Key words

cytochrome P450 (CYP) evidence-based prevention (EBP) lung cancer polymorphism bronchial epithelium 



cytochrome P450


single-nucleotide polymorphism


evidence-based prevention


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. (1).
    Uramoto H, Nakanishi R, Fujino Y, Imoto H, Takenoyama M, Yoshimatsu T, et al. Prediction of pulmonary complications after a lobectomy in patients with non-small cell lung cancer. Thorax. 2001; 56: 59–61.PubMedCrossRefGoogle Scholar
  2. (2).
    Osaki T, Mitsudomi T, Oyama T, Nakanishi R, Yasumoto K. Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest. 1995; 108: 157–162.PubMedCrossRefGoogle Scholar
  3. (3).
    Gu CD, Osaki T, Oyama T, Inoue M, Kodate M, Dobashi K, et al. Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer; Impact on recurrence and survival. Ann Surg. 2001; 233: 133–139.Google Scholar
  4. (4).
    Osaki T, Oyama T, Inoue M, Gu CD, Kodate M, Aikawa M, et al. Molecular biological markers and micrometastasis in reseeted non-small-cell lung cancer. Prognostic implications. Jpn J Thorac Cardiovasc Surg. 2001; 49: 545–551.PubMedCrossRefGoogle Scholar
  5. (5).
    Osaki T, Ovama T, Gu CD, Yamashita T, So T, Takenoyama M, et al. Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage 1 non-small-cell lung cancer. J Clin Oncol. 2002; 20: 2930–2936.PubMedCrossRefGoogle Scholar
  6. (6).
    Oyma T, Kawamoto T, Matsuno M, Osaki T, Matsumoto A, Isse T, et al. A case-case study comparing the usefulness of serum trace elements (Cu, Zn and Se) and tumor markers (CEA, SCC and SLX) in non-small cell lung cancer patients. Anticancer Res. 2003; 23: 605–612.Google Scholar
  7. (7).
    Gu CD, Oyama T, Osaki T, Li J, Takenoyama M, Izumi H, et al. Low expression of polypeptide GalNac N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: Impact on poor prognosis and early recurence. Br J Cancer. 2004; 90: 436–442.PubMedCrossRefGoogle Scholar
  8. (8).
    Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, et al. Expression of delta Np73 predicts poor prognosis in lung cancer. Clin Cancer Res. 2004; 10: 6905–6911.PubMedCrossRefGoogle Scholar
  9. (9).
    Iwata T, Uramoto H, Sugio K, Fujino Y, Oyama T, Nakata S, et al. A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer. Lung Cancer. 2005; 50: 67–73.PubMedCrossRefGoogle Scholar
  10. (10).
    Oyama T, Osaki T, Baba T, Nagata Y, Mizukami M, So T, et al. Molecular genetic tumor markers in non-small cell lung cancer. Anticancer Res. 2005; 25: 1193–1196.PubMedGoogle Scholar
  11. (11).
    Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Yoshimastu T, et al. Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer. 2005; 49: 55–62.PubMedCrossRefGoogle Scholar
  12. (12).
    Uramoto H, Sugio K, Oyama T, Ono K, Sugaya M, Yoshimatsu T, et al. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer. 2005 (in press).Google Scholar
  13. (13).
    Yoshimatsu T, Uramoto H, Oyama T, Yashima Y, Gu C, Morita M, et al. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer. Anticancer Res. 2005; 25: 3437–3443.PubMedGoogle Scholar
  14. (14).
    Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J Natl Cancer Inst. 1993; 85: 2018–2023.PubMedCrossRefGoogle Scholar
  15. (15).
    Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Sugio K, et al. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin Cancer Res. 1996; 2: 1185–1189.PubMedGoogle Scholar
  16. (16).
    Kawamoto T, Isse T, Kumugita N, Yang M, Kitagawa K, Suenaga R, et al. Effects of genetic polymorphism of drug metabolizing enzymes on smoking and drinking. J UOEH. 2003; 25: 97–106.Google Scholar
  17. (17).
    Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992; 268: 2420–2425.CrossRefGoogle Scholar
  18. (18).
    Oyama T, Kawamoto T, Matsumoto A, Isse T, Ozaki S, Yasumoto K. Evidence based prevention (EBP): Evidencebased approach to prevention of lung cancer by application of cytochrome 2E1 polymorphism. J UOEH. 2002; 24: 413–421.PubMedGoogle Scholar
  19. (19).
    Oyama T, Matsumoto A, Isse T, Kim Y-D, Ozaki S, Osaki T, et al. Evidence-based prevention (EBP): Approach to lung cancer prevention based on cytochrome 1A1 and cytochrome 2E1 polymorphism. Anticancer Res. 2003; 23: 1731–1738.PubMedGoogle Scholar
  20. (20).
    Sobue T, Yamamoto S, Hara M, Sasazuki S, Sasaki S, Tsugane S, et al. Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women: the JPHC study. Int J Cancer. 2002; 99: 245–251.PubMedCrossRefGoogle Scholar
  21. (21).
    Oyama T, Mitsudomi T, Kawamoto T, Ogami A, Osaki T, Kodama Y, et al. Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese. Int Arch Occup Environ Health. 1995; 67: 253–256.PubMedCrossRefGoogle Scholar
  22. (22).
    Oyama T, Kawamoto T, Mizoue T, Nishida K, Osaki T, Sugio K, et al. p53 mutations of lung cancer are not significantly affected by CYP1A1 or GSTM1 polymorphisms. Int J. Oncol. 1997; 11: 305–309.Google Scholar
  23. (23).
    Oyama T, Kawamoto T, Mizoue T, Sugio K, Kodama Y, Mitsudomi T, et al. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res. 1997; 17: 583–587.PubMedGoogle Scholar
  24. (24).
    Oyama T, Osaki T, Mitsudomi T, Ogawa R, Nakanishi R, Sugio K, et al. p53 alteration, proliferating cell nuclear antigen, and nucleolar organizer regions in thymic epithelial tumors. Int J Mol Med. 1998; 1: 823–826.PubMedGoogle Scholar
  25. (25).
    Oyama T, Osaki T, Nose N, Ichiki Y, Inoue M, Imoto H, et al. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in nonsmall cell lung carcinoma. Anticancer Res. 2000; 20: 505–510.PubMedGoogle Scholar
  26. (26).
    Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M, Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res. 1996; 56: 72–76.PubMedGoogle Scholar
  27. (27).
    Oyama T, Kagawa N, Kim Y-D, Matsumoto A, Isse T, Kawamoto T. Lung cancer and CYP1A1 or GSTM1 polymorphism. Environ Health Prev Med. 2003; 7: 230–234.CrossRefGoogle Scholar
  28. (28).
    Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res. 2001; 482: 11–19.PubMedGoogle Scholar
  29. (29).
    Goto I, Yoneda S, Yamamoto M, Kawajiri K. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res. 1996; 56: 3725–3730.PubMedGoogle Scholar
  30. (30).
    Crawford EL, Weaver DA, DeMuth JP, Jackson CM, Khuder SA, Frampton MW, et al. Measurement of cytochrome P450 2A6 and 2E1 gene expression in primary human bronchial epithelial cells. Carcinogenesis. 1998; 19: 1867–1871.PubMedCrossRefGoogle Scholar
  31. (31).
    Oyama T, Isse T, Kagawa N, Kinaga T, Kim YD, Morita M, et al. Tissue-distribution of aldehyde dehydrogenase 2 and effects of the ALDH2 gene-disruption on the expression of enzymes involved in alcohol metabolism. Front Biosci. 2005; 10: 951–960.PubMedCrossRefGoogle Scholar
  32. (32).
    Hukkanen J, Pelkonen O, Hakkola J, Raunio H. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol. 2002; 32: 391–411.PubMedCrossRefGoogle Scholar
  33. (33).
    Berge G, Mollerup S, OVrebo S, Hewer A, Phillips DH, Eilertsen E, et al. Role of estrogen receptor in regulation of polycyclic aromatic hydrocarbon metabolic activation in lung. Lung Cancer. 2004; 45: 289–297.PubMedCrossRefGoogle Scholar
  34. (34).
    Port JL, Yamaguchi K, Du B, De Lorenzo M, Chang M, Heerdt PM, et al. Tobacco smoke induces CYP1B1 in the aerodigestive tract. Carcinogenesis. 2004; 25: 2275–2281.PubMedCrossRefGoogle Scholar
  35. (35).
    Runge DM, Stock TW, Lehmann T, Taege C, Bernauer U, Stolz DB, et al. Expression of cytochrome P450 2E1 in normal human bronchial epithelial cells and activation by ethanol in culture. Arch Toxicol. 2001; 75: 335–337.PubMedCrossRefGoogle Scholar
  36. (36).
    Raunio H, Hakkola J, Hukkanen J, Lassila A, Paivarinta K, Pelkonen O, et al. Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Exp Toxicol Pathol. 1999; 51: 412–417.PubMedGoogle Scholar
  37. (37).
    Raunio H, Hakkola J, Pelkonen O. Regulation of CYP3A genes in the human respiratory tract. Chem Biol Interact. 2005; 151: 53–62.PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Society of Hygiene 2006

Authors and Affiliations

  • Tsunehiro Oyama
    • 1
  • Toyohi Isse
    • 1
  • Tomoe Murakami
    • 1
  • Rie Suzuki-Narai
    • 1
  • Masanori Ogawa
    • 1
  • Tetsunosuke Yamaguchi
    • 1
  • Tsuyoshi Kinaga
    • 1
  • Yasunori Yashima
    • 1
  • Shinichi Ozaki
    • 1
  • Yong-Dae Kim
    • 2
  • Heon Kim
    • 2
  • Toshihiro Kawamoto
    • 1
  1. 1.Department of Environmental HealthUniversity of Occupational and Environmental HealthKitakyushuJapan
  2. 2.Department of Preventive Medicine, College of MedicineChungbuk National UniversityCheongjuKorea

Personalised recommendations